Edition:
India

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

3.14USD
15 Dec 2017
Change (% chg)

$-0.51 (-13.97%)
Prev Close
$3.65
Open
$3.27
Day's High
$3.30
Day's Low
$3.12
Volume
934,499
Avg. Vol
223,995
52-wk High
$5.71
52-wk Low
$1.08

Latest Key Developments (Source: Significant Developments)

Verastem Announces Pricing Of Public Offering Of Common Stock
Friday, 15 Dec 2017 

Verastem Inc ::VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - ANNOUNCED PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $25 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Verastem Announces Public Offering Of Common Stock
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Verastem Inc ::VERASTEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​
Monday, 11 Dec 2017 

Dec 10 (Reuters) - Verastem Inc ::‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​.‍DUO STUDY ACHIEVES PRIMARY ENDPOINT, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS FOR DUVELISIB VERSUS OFATUMUMAB​.‍PLANS TO SUBMIT A NDA TO U.S. FDA REQUESTING FULL APPROVAL OF DUVELISIB​.‍PLANS TO SUBMIT ACCELERATED APPROVAL OF DUVELISIB FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY FL ​.‍EXPECTS TO SUBMIT DUVELISIB NDA DURING Q1 OF 2018​.  Full Article

Verastem reports Q3 loss per share of $0.61
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Verastem Inc :Verastem reports third quarter 2017 financial results.Q3 loss per share $0.61.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Verastem - based on current plans,​ ‍expect to have sufficient cash, cash equivalents & investments to fund research and development programs & operations into H2 2018.  Full Article

Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Verastem Inc -:Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA.Verastem Inc - ‍plans to submit NDA for duvelisib during Q1 of 2018​.  Full Article

Verastem reports Q2 loss per share $0.23
Monday, 8 Aug 2016 

Verastem Inc : Verastem reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S .Expect to have sufficient cash, cash equivalents and short-term investments to fund research and development programs and operations into 2018.  Full Article

Verastem Q1 loss per share $0.22
Tuesday, 10 May 2016 

Verastem Inc : Expect to have sufficient cash, cash equivalents,short-term investments to fund research and development programs and operations into 2018 . Verastem reports first quarter 2016 financial results . Q1 loss per share $0.22 .Q1 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article